Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected Stage II or III colon cancer

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3255-3262

  Abrams, Thomas A ^a   Brightly, Rick ^c   Mao, Jianbin ^c   Kirkner, Gregory ^b   Meyerhardt, Jeffrey A ^a   Schrag, Deborah ^a   Fuchs, Charles S ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c IntrinsiQ   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHYSICAL DISABILITY; PRIORITY JOURNAL; PRIVATE PRACTICE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PHYSICIAN'S PRACTICE PATTERNS; WITHHOLDING TREATMENT;

EID: 80051984485     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.0058     Document Type: Article

References (34)

1. O'Connell M.J., Mailliard J.A., Kahn M.J., et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997 (Pubitemid 27020580)
2. Moertel C.G., Fleming T.R., Macdonald J.S., et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
3. Moertel C.G., Fleming T.R., Macdonald J.S., et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990 (Pubitemid 20042739)
4. André T., Boni C., Mounedji-Boudiaf L., et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004 (Pubitemid 38702845)
5. Haller D.G., Cassidy J., Tabernero J., et al: Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS). 2010 Gastrointestinal Cancers Symposium (abstr 284)
6. Kuebler J.P., Wieand H.S., O'Connell M.J., et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007 (Pubitemid 46954643)
7. André T., Boni C., Navarro M., et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
8. Keating N.L., Landrum M.B., Klabunde C.N., et al: Adjuvant chemotherapy for stage III colon cancer: Do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26:2532-2537, 2008
9. Etzioni D.A., El-Khoueiry A.B., Beart R.W. Jr: Rates and predictors of chemotherapy use for stage III colon cancer: A systematic review. Cancer 113: 3279-3289, 2008
10. Cronin D.P., Harlan L.C., Potosky A.L., et al: Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 101:2308- 2318, 2006
11. Wirtzfeld D.A., Mikula L., Gryfe R., et al: Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: Experience in 2 Canadian provinces. Can J Surg 52:92-97, 2009
12. Osarogiagbon R.U., Sachdev J.C., Khattak A.G., et al: Pattern of use of adjuvant chemotherapy for stage II colon cancer: A single-institution experience. Clin Colorectal Cancer 8:94-99, 2009
13. Renouf D., Kennecke H., Gill S.: Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer 7:386-389, 2008
14. Wu X., Chen V.W., Andrews P.A., et al: Treatment patterns for stage III colon cancer and factors related to receipt of postoperative chemotherapy in Louisiana. J La State Med Soc 156:255-261, 2004
15. Dobie S.A., Baldwin L.M., Dominitz J.A., et al: Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 98:610-619, 2006 (Pubitemid 43904844)
16. De Gramont A., Banzi M., Navarro M., et al: Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized MOSAIC trial. Proc Am Soc Clin Oncol 22:253, 2003 (abstr 1015)
17. Haller D.G., Catalano P.J., Macdonald J.S., et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23:8671-8678, 2005 (Pubitemid 46211510)
18. Iwashyna T.J., Lamont E.B.: Effectiveness of adjuvant fluorouracil in clinical practice: A populationbased cohort study of elderly patients with stage III colon cancer. J Clin Oncol 20:3992-3998, 2002
19. Engstrom P.F., Arnoletti J.P., Benson A.B. 3rd, et al: NCCN Clinical Practice Guidelines in Oncology: Colon cancer. J Natl Compr Canc Netw 7:778-831, 2009
20. Wolmark N., Yothers G., O'Connell M.J., et al: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 27:6s, 2009 (suppl; abstr LBA4)
21. De Gramont A., Boni C., Navarro M., et al: Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 25:165s, 2007 (suppl; abstr 4007)
22. National Cancer Institute: Cancer Drug Information: FDA Approval for Oxaliplatin. http://www.cancer.gov/cancertopics/druginfo/fda-oxaliplatin#Anchor- Adjuvan-64761
23. Centers for Medicare & Medicaid Services: Decision Memo for Anticancer Chemotherapy for Colorectal Cancer (CAG-00179N). http://www.cmms.hhs. gov/medicare-coverage-database/details/nca-decisionmemo.aspx?NCAId=90&ver= 23&NcaName=Anticancer+Chemotherapy+for+Colorectal+Cancer&bc= BEAAAAAAEAAA&
24. Cassidy J., Clarke S., Diaz-Rubio E., et al: XELOX-1/NO16966, a randomized phase III trial of first-line XELOX compared with FOLFOX4 for patients with metastatic colorectal cancer (MCRC): Updated survival and tolerability results. 2009 Gastrointestinal Cancers Symposium (abstr 382)
25. De Gramont A., Van Cutsem E., Tabernero J., et al: AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. 2011 Gastrointestinal Cancers Symposium, January 19-21, 2011 (abstr 362)
26. Roche: Phase III C-08 study of Avastin in earlystage colon cancer does not meet primary endpoint. Media release, April 22, 2009. http://www.roche.com/ media/media-releases/med-cor-2009-04-22.htm
27. Jessup J.M., Stewart A., Greene F.L., et al: Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 294:2703-2711, 2005 (Pubitemid 41770099)
28. Ayanian J.Z., Zaslavsky A.M., Fuchs C.S., et al: Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 21:1293-1300, 2003 (Pubitemid 46606406)
29. Schrag D., Rifas-Shiman S., Saltz L., et al: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999-4005, 2002
30. Potosky A.L., Harlan L.C., Kaplan R.S., et al: Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20:1192-1202, 2002 (Pubitemid 34177424)
31. Sundararajan V., Grann V.R., Jacobson J.S., et al: Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: A population-based study. Cancer J 7:213-218, 2001
32. Schrag D., Cramer L.D., Bach P.B., et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001 (Pubitemid 32590779)
33. Meyerhardt J.A., Catalano P.J., Schrag D., et al: Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med 139:649-657, 2003
34. Hodgson D.C., Fuchs C.S., Ayanian J.Z.: Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 93:501-515, 2001 (Pubitemid 32318429)